Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima
- Company
- ANAPTYSBIO, INC (ANAB)
- Indication
- Lung Cancer, Non-Small Cell
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.